Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Prepaid Assets (2023 - 2026)

Indivior Pharmaceuticals has reported Prepaid Assets over the past 4 years, most recently at $40.0 million for Q1 2026.

  • For Q1 2026, Prepaid Assets fell 28.57% year-over-year to $40.0 million; the TTM value through Mar 2026 reached $40.0 million, down 28.57%, while the annual FY2025 figure was $34.0 million, 9.68% up from the prior year.
  • Prepaid Assets for Q1 2026 was $40.0 million at Indivior Pharmaceuticals, up from $34.0 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $56.0 million in Q1 2025 and troughed at $19.0 million in Q3 2025.
  • A 4-year average of $37.1 million and a median of $34.0 million in 2025 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: plummeted 40.38% in 2024 and later rose 9.68% in 2025.
  • Year by year, Prepaid Assets stood at $52.0 million in 2023, then plummeted by 40.38% to $31.0 million in 2024, then increased by 9.68% to $34.0 million in 2025, then increased by 17.65% to $40.0 million in 2026.
  • Business Quant data shows Prepaid Assets for INDV at $40.0 million in Q1 2026, $34.0 million in Q4 2025, and $19.0 million in Q3 2025.